Frank J. Calzone
22Patents
9h-index
13Co-inventors
72Inventor score
Filing activity: Dec 22, 1995 → Feb 23, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6284485A | Nucleic acids encoding osteoprotegerin | Chemistry; Metallurgy | 85 | Expired |
| US6015938A | Osteoprotegerin | Chemistry; Metallurgy | 77 | Expired |
| US6369027B1 | Osteoprotegerin | Chemistry; Metallurgy | 28 | Expired |
| US6288032A | Osteoprotegerin | Chemistry; Metallurgy | 24 | Expired |
| US6284740A | Osteoprotegerin | Chemistry; Metallurgy | 24 | Expired |
| US6284728A | Osteoprotegerin | Chemistry; Metallurgy | 23 | Expired |
| US7871611B2 | Compositions and methods relating to anti IGF-1 receptor antibodies | Chemistry; Metallurgy | 18 | Active |
| US6767541B2 | HER-2/neu overexpression abrogates growth inhibitory pathways | Chemistry; Metallurgy | 13 | Expired |
| US8168409B2 | Compositions and methods relating to anti-IGF-1 receptor antibodies | Chemistry; Metallurgy | 11 | Active |
| US6613544B1 | Osteoprotegerin | Chemistry; Metallurgy | 5 | Expired |
| US8460662B2 | Compositions and methods relating to anti-IGF-1 receptor antibodies | Chemistry; Metallurgy | 3 | Active |
| US7005413B1 | Combination therapy for conditions leading to bone loss | Chemistry; Metallurgy | 3 | Expired |
| US11319372B2 | Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) | Chemistry; Metallurgy | 2 | Active |
| US8895008B2 | Compositions and methods relating to anti-IGF-1 receptor antibodies | Chemistry; Metallurgy | 1 | Active |
| US11248049B2 | Immunotherapy using antibodies that bind Programmed Death 1 (PD-1) | Chemistry; Metallurgy | 0 | Active |
| US11629184B2 | Calcitonin gene-related peptide (CGRP) antagonist antibodies | Chemistry; Metallurgy | 0 | Active |
| US7632922B1 | Osteoprotegerin | Physics | 0 | Expired |
| US11332531B2 | Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1) | Chemistry; Metallurgy | 0 | Active |
| US11242398B2 | Anti-OX40 antibodies and methods of activating OX40 | Chemistry; Metallurgy | 0 | Active |
| US11319376B2 | Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US11078288B2 | Methods and compositions for treating tumor diseases | Chemistry; Metallurgy | 0 | Active |
| US10035861B2 | Compositions and methods relating to anti-IGF-1 receptor antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.